• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

SAR-260301 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5755501

SAR-260301 is an orally available and selective inhibitor of PI3Kbeta (IC50: 23nM). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
SAR-260301, Inhibitor
Full Product Name
SAR-260301
Product Gene Name
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
354.4
Solubility
DMSO: 125mg/mL (352.71mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C19H22N4O3
SMILES
O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1
CAS Number
1260612-13-2
Target & IC50
PI3Kbeta: ic50 23nM
PI3Kdelta: ic50 468nM
PI3Kalpha: ic50 1539nM
PI3Kgamma: ic50 10000nM
Vps34: ic50 183nM
PI3KC2gamma: ic50 3812nM
pAkt: ic50 49nM
DNA-PK: ic50 2000nM

Product Categories/Family for SAR-260301, inhibitor

Product References and Citations for SAR-260301, inhibitor

Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment,of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20.
Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kbeta inhibitors for the treatment,of phosphatase and tensin homologue (PTEN)-deficient cancers. J Med Chem. 2014 Feb 13;57(3):903-20.
Bonnevaux H, et al. Concomitant Inhibition of PI3Kbeta and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma treatment, Preclinical Assessment of SAR260301 Oral PI3Kbeta-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.
Bonnevaux H, et al. Concomitant Inhibition of PI3Kbeta and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma treatment, Preclinical Assessment of SAR260301 Oral PI3Kbeta-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15(7):1460-71.

Other Notes

Small volumes of SAR-260301, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for SAR-260301 purchase

MBS5755501 is an inhibitor targeting SAR-260301.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000